Genomics of Lung Cancer may Change Diagnosis, Prognosis and Therapy

László KOPPER1, József TÍMÁR2

11st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Budapest, Hungary
2Department of Tumor Progression, National Institute of Oncology, Budapest, Hungary


Despite significant improvements in tumor management in general, the prognosis of lung cancer patients remains dismal. It is a hope that our increasing knowledge in molecular aspects of tumor development, growth and progression will open new targets for therapeutic interventions. In this review we discuss some of the more recent results of this field. This includes the susceptibility factors, an association between genetic changes in EGFR pathway and tyrosine kinase inhibitors, the role of gene hypermethylation and genetic profiling, as well as different molecular aspects of tumor progression. Available data all support that lung cancer is a group of diseases with not only distinct histological but with similarly different genetic characters. Accordingly, the diagnosis, prognosis and therapy must accommodate this heterogeneity. Pathology & Oncology Research, Vol 11, Nr 1, 5-10, 2005

Key words: lung cancer; genomics

Received: Feb 10, 2005; accepted: Mar 3, 2005
Correspondence: László KOPPER, 1st Institute of Pathology and Experimental Cancer Research, Semmelweis University, Üllõi út 26. Budapest H-1085, Hungary; Tel: +36-1-317-0891, Fax: +36-1-317-0891; E-mail:

Click here to get the full-text version in PDF!